Differential regulation of cyclin-dependent kinase inhibitors in neuroblastoma cells

Biochemical and Biophysical Research Communications

Volumn 435, Issue 2, 2013, Pages 295-299

  Qiao, Lan ^a,c   Paul, Pritha ^a,b   Lee, Sora ^a,b   Qiao, Jingbo ^a   Wang, Yongsheng ^c   Chung, Dai H ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JILIN UNIVERSITY   (China)

Author keywords

GRP; Neuroblastoma; P21; P27; PTEN

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; GASTRIN RELEASING PEPTIDE; GASTRIN RELEASING PEPTIDE RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P21; PROTEIN P27;

ARTICLE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CYTOPLASM; DNA SYNTHESIS; HUMAN; HUMAN CELL; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; GASTRIN-RELEASING PEPTIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEUROBLASTOMA; PTEN PHOSPHOHYDROLASE; RECEPTORS, BOMBESIN;

EID: 84878470902     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.04.023     Document Type: Article

References (26)

1. Qiao J., Kang J., Cree J., Evers B.M., Chung D.H. Gastrin-releasing peptide-induced down-regulation of tumor suppressor protein PTEN (phosphatase and tensin homolog deleted on chromosome ten) in neuroblastomas. Ann. Surg. 2005, 241:684-691. discussion 691-682.
2. Qiao J., Kang J., Ishola T.A., Rychahou P.G., Evers B.M., Chung D.H. Gastrin-releasing peptide receptor silencing suppresses the tumorigenesis and metastatic potential of neuroblastoma. Proc. Natl. Acad. Sci. USA 2008, 105:12891-12896.
3. Engelman J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 2009, 9:550-562.
4. Chalhoub N., Baker S.J. PTEN and the PI3-kinase pathway in cancer. Annu. Rev. Pathol. 2009, 4:127-150.
5. Ishola T.A., Kang J., Qiao J., Evers B.M., Chung D.H. Phosphatidylinositol 3-kinase regulation of gastrin-releasing peptide-induced cell cycle progression in neuroblastoma cells. Biochim. Biophys. Acta 2007, 1770:927-932.
6. LaBaer J., Garrett M.D., Stevenson L.F., Slingerland J.M., Sandhu C., Chou H.S., Fattaey A., Harlow E. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 1997, 11:847-862.
7. Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13:1501-1512.
8. el-Deiry W.S., Harper J.W., O'Connor P.M., Velculescu V.E., Canman C.E., Jackman J., Pietenpol J.A., Burrell M., Hill D.E., Wang Y., et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994, 54:1169-1174.
9. Fontana L., Fiori M.E., Albini S., Cifaldi L., Giovinazzi S., Forloni M., Boldrini R., Donfrancesco A., Federici V., Giacomini P., Peschle C., Fruci D. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS ONE 2008, 3:e2236.
10. Hiromura K., Pippin J.W., Fero M.L., Roberts J.M., Shankland S.J. Modulation of apoptosis by the cyclin-dependent kinase inhibitor p27(Kip1). J. Clin. Invest. 1999, 103:597-604.
11. Matsuo T., Seth P., Thiele C.J. Increased expression of p27Kip1 arrests neuroblastoma cell growth. Med. Pediatr. Oncol. 2001, 36:97-99.
12. Munoz J.P., Sanchez J.R., Maccioni R.B. Regulation of p27 in the process of neuroblastoma N2A differentiation. J. Cell. Biochem. 2003, 89:539-549.
13. Rossig L., Jadidi A.S., Urbich C., Badorff C., Zeiher A.M., Dimmeler S. Akt-dependent phosphorylation of p21(Cip1) regulates PCNA binding and proliferation of endothelial cells. Mol. Cell. Biol. 2001, 21:5644-5657.
14. Sun H., Lesche R., Li D.M., Liliental J., Zhang H., Gao J., Gavrilova N., Mueller B., Liu X., Wu H. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc. Natl. Acad. Sci. USA 1999, 96:6199-6204.
15. Qiao J., Lee S., Paul P., Qiao L., Taylor C.J., Schlegel C., Colon N.C., Chung D.H. Akt2 regulates metastatic potential in neuroblastoma. PLoS ONE 2013, 8:e56382.
16. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657.
17. Liang J., Slingerland J.M. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003, 2:339-345.
18. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 2005, 4:988-1004.
19. Paul P., Gillory L.A., Kang J., Qiao J., Chung D.H. Targeting gastrin-releasing peptide as a new approach to treat aggressive refractory neuroblastomas. Surgery 2011, 149:425-432.
20. Halvorsen O.J., Haukaas S.A., Akslen L.A. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin. Cancer Res. 2003, 9:1474-1479.
21. Andres-Pons A., Gil A., Oliver M.D., Sotelo N.S., Pulido R. Cytoplasmic p27Kip1 counteracts the pro-apoptotic function of the open conformation of PTEN by retention and destabilization of PTEN outside of the nucleus. Cell. Signal. 2012, 24:577-587.
22. Chung J.H., Eng C. Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis. Cancer Res. 2005, 65:8096-8100.
23. Besson A., Dowdy S.F., Roberts J.M. CDK inhibitors: cell cycle regulators and beyond. Dev. Cell 2008, 14:159-169.
24. Chu I.M., Hengst L., Slingerland J.M. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat. Rev. Cancer 2008, 8:253-267.
25. Lee J., Kim S.S. The function of p27 KIP1 during tumor development. Exp. Mol. Med. 2009, 41:765-771.
26. Wander S.A., Zhao D., Slingerland J.M. P27: a barometer of signaling deregulation and potential predictor of response to targeted therapies. Clin. Cancer Res. 2011, 17:12-18.